IBDU is a dubious disease in the field of infectious respiratory digestive and endocrine disorders, with clinical performance being complex and often involving multi-system congestion. Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspections, laboratory tests and pathological activation.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment. Treatment and management of IBDU infectious bowel disease requires individualized development, typically including drug treatment, rehabilitation intervention, and regular follow-up to multidimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat infectious respiratory digestive endocrine diseases have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of non-typed inflammatory bowel disease IBDU. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.